237 related articles for article (PubMed ID: 11903952)
1. Problems associated with the clinical use of proton pump inhibitors.
Gillen D; McColl KE
Pharmacol Toxicol; 2001 Dec; 89(6):281-6. PubMed ID: 11903952
[TBL] [Abstract][Full Text] [Related]
2. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
Laine L; Ahnen D; McClain C; Solcia E; Walsh JH
Aliment Pharmacol Ther; 2000 Jun; 14(6):651-68. PubMed ID: 10848649
[TBL] [Abstract][Full Text] [Related]
3. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.
Kuipers EJ; Lundell L; Klinkenberg-Knol EC; Havu N; Festen HP; Liedman B; Lamers CB; Jansen JB; Dalenback J; Snel P; Nelis GF; Meuwissen SG
N Engl J Med; 1996 Apr; 334(16):1018-22. PubMed ID: 8598839
[TBL] [Abstract][Full Text] [Related]
4. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis.
Sanduleanu S; Jonkers D; De Bruïne A; Hameeteman W; Stockbrügger RW
Aliment Pharmacol Ther; 2001 Aug; 15(8):1163-75. PubMed ID: 11472319
[TBL] [Abstract][Full Text] [Related]
5. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors and H. pylori infection: why the concern?
Weinstein WM
Curr Gastroenterol Rep; 1999 Dec; 1(6):507-10. PubMed ID: 10980994
[TBL] [Abstract][Full Text] [Related]
7. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.
Waldum HL; Brenna E; Sandvik AK
Expert Opin Drug Saf; 2002 May; 1(1):29-38. PubMed ID: 12904157
[TBL] [Abstract][Full Text] [Related]
9. Review article: the development of atrophic gastritis--Helicobacter pylori and the effects of acid suppressive therapy.
Kuipers EJ; Lee A; Klinkenberg-Knol EC; Meuwissen SG
Aliment Pharmacol Ther; 1995 Aug; 9(4):331-40. PubMed ID: 8527609
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and gastric neoplasia.
Kuipers EJ
Gut; 2006 Sep; 55(9):1217-21. PubMed ID: 16905689
[TBL] [Abstract][Full Text] [Related]
11. The safety of proton pump inhibitors.
Waldum HL
Aliment Pharmacol Ther; 2001 May; 15(5):729-30. PubMed ID: 11328270
[No Abstract] [Full Text] [Related]
12. Rebound hypersecretion after omeprazole.
Friedel DM; Gbadehan E
Gastroenterology; 1999 Aug; 117(2):513-4. PubMed ID: 10465638
[No Abstract] [Full Text] [Related]
13. Eradication of Helicobacter pylori heals atrophic corpus gastritis caused by long-term treatment with omeprazole.
Stolte M; Meining A; Koop H; Seifert E
Virchows Arch; 1999 Jan; 434(1):91-4. PubMed ID: 10071241
[TBL] [Abstract][Full Text] [Related]
14. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa.
Sanduleanu S; Jonkers D; De Bruine A; Hameeteman W; Stockbrügger RW
Aliment Pharmacol Ther; 2001 Mar; 15(3):379-88. PubMed ID: 11207513
[TBL] [Abstract][Full Text] [Related]
15. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Howden CW
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
[TBL] [Abstract][Full Text] [Related]
16. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
Holtmann G; Layer P; Goebell H
Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent eradication of Helicobacter pylori with dual therapy.
Treiber G; Ammon S; Klotz U
Aliment Pharmacol Ther; 1997 Aug; 11(4):711-8. PubMed ID: 9305480
[TBL] [Abstract][Full Text] [Related]
18. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report.
Malfertheiner P; Mégraud F; O'Morain C; Hungin AP; Jones R; Axon A; Graham DY; Tytgat G;
Aliment Pharmacol Ther; 2002 Feb; 16(2):167-80. PubMed ID: 11860399
[TBL] [Abstract][Full Text] [Related]
19. Gastric corpus IL-8 concentration and neutrophil infiltration in duodenal ulcer patients.
Uemura N; Oomoto Y; Mukai T; Okamoto S; Yamaguchi S; Mashiba H; Taniyama K; Sasaki N; Sumii K; Haruma K; Kajiyama G
Aliment Pharmacol Ther; 1997 Aug; 11(4):793-800. PubMed ID: 9305491
[TBL] [Abstract][Full Text] [Related]
20. Atrophic gastritis and Helicobacter pylori in reflux esophagitis.
Repucci AH
N Engl J Med; 1996 Sep; 335(10):750-1. PubMed ID: 8786770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
